Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

Centre Hospitalier Universitaire Vaudois, Lausanne

Universitätsspital Bern, Inselspital, Bern

Kantonsspital St. Gallen, Sankt Gallen

Institut Paoli Calmettes, Marseille

CHRU Besançon, Besançon

Hospital Lucus Augusti, Lugo

M.D. Anderson Center Madrid, Madrid

Hospital Universitario 12 de Octubre, Madrid

CHU de Nîmes - Institut de Cancérologie du Gard, Nîmes

Institut Claudius Régaud, Toulouse

Institut de Cancérologie de l'Ouest, Saint-Herblain

Institut de Cancérologie de Lorraine, Nancy

Centre Jean Perrin, Clermont-Ferrand

CHU Strasbourg, Strasbourg

Centre Léon Bérard, Lyon

Centre Hospitalier Lyon Sud, Pierre-Bénite

Institut Mutualiste Montsouris, Paris

Gustave Roussy, Villejuif

SALK - Salzburger Landesklinik, Salzburg

Universitätsmedzin Charité, Berlin

University Hospital Carl Gustav Carus Dresden, Dresden

Universitätsklinikum Essen, Essen

University Cancer Center Hamburg Eppendorf, Hamburg

Medizinische Hochschule Hannover, Hanover

Klinikum Der Friedrich-Schiller-Universitaet Jena, Jena

Universitätsklinikum Schleswig-Holstein, Lübeck

Otto-von-Guericke-Universität University hospital Magdeburg, Magdeburg

University, Hospital Münster, Münster

Caritas Krankenhaus St.Josef Klinik für Urologie, Regensburg

University Hospital Tuebingen, Tübingen

The Netherlands Cancer Institute - Oncology, Amsterdam

Maxima Medisch Centrum, Eindhoven

Leiden University Medical Center, Leiden

Universitair Medisch Centrum Utrecht, Utrecht

Hospital de La Santa Creu i Sant Pau, Barcelona

Western General Hospital - Edinburgh Cancer Centre, Edinburgh

Beatson West of Scotland Cancer Centre, Glasgow

The Christie NHS Foundation Trust, Manchester

Mount Vernon Hospital, Northwood

Royal Cornwall Hospital (RCH) - Sunrise Centre, Truro